Is RVTY a good stock to buy?
Revvity, Inc. · end-of-day data as of Nov 13, 2026
- Trendbullish
- MAs3 of 4
- Sector▲ +15.9%
- Earnings in80d
- P/E68.3x
- RSI49
- Support-2.7%
- Off 52w high-10.1%
- Volume0.7x
- Bollingerlower half
- News
- FCF yield+3.4%
- ConsensusHold · 18
- 52w range$81–$172
- ATR+4.9%
- Off ATH-24.0%
- MA20×50↓ in ~21d
- PT$129.46 -16.1%
- P/E vs own+30.1%
- P/E vs sector+112.1%
- Insiders-$1.28M
- MACD-1.03
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Revvity a good stock to buy?
Revvity is strong on 2 of the 5 questions about the business; weak on demand. The price is high: 68.3 times its earnings, above its 3-year median of 46.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand shrinking
- Advantage some edge
- Economics profitable
- Execution delivers
- Fragility sturdy
- Price expensive
RVTY sales growth revenue growth
-5%a year, for the last 3 yearsRevvity's sales fell 5% a year for 3 years, to $2.86B in fiscal 2025.
RVTY analysts' forecast revenue estimates
0%the sales they expect next fiscal year, on the lastAnalysts expect Revvity's sales to grow 0% to $2.87B in fiscal 2026 (12 analysts).
RVTY competitors
pretickt analysis+5%its sales in 12 months, on a year before
Revvity's sales grew 5% in the 12 months to Oct 4, 2026, faster than Charles River Laboratories (-1%), slower than Quest Diagnostics (+9%), Labcorp (+6%) and Illumina (+6%).
RVTY sales by business revenue by segment
50%of its sales from Life SciencesLife Sciences brought Revvity 50% of its sales in fiscal 2025; Diagnostics 50%.
RVTY return on capital ROIC
pretickt analysis4%earned before tax on the money invested in itRevvity earned 4% before tax on the capital invested in it in the 12 months to Oct 4, 2026; Illumina 25%, Quest Diagnostics 13%, Labcorp 11% and Charles River Laboratories 10%.
RVTY margin on each sale gross margin
53%left after making the productRevvity kept 53% of each sale after making the product in the 12 months to Oct 4, 2026; its competitors' median is 33%.
RVTY margin after costs profit margin
13%of sales left after running the businessRevvity's operating margin was 13% in the 12 months to Oct 4, 2026, against 24% in fiscal 2022.
RVTY earnings vs estimates
8 of 8quarters above the analysts' estimateRevvity beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 3, 2026.
RVTY insider selling
-$5.97Msold, net, by its executives in 12 monthsRevvity's executives and directors sold a net $5.97M of shares in the 12 months to Nov 13, 2026; none bought.
RVTY number of employees
0%about as many people as a year beforeRevvity had 11,000 employees at the end of fiscal 2025, about as many as a year before.
RVTY CEO pay
$13.81Mfor fiscal 2025, 74% of it in stock and optionsRevvity paid its CEO $13.81M for fiscal 2025, 74% of it in stock and options.
RVTY financial health Altman Z-score
3.7Altman Z-score, safe above 3Revvity's Altman Z-score is 3.7 (Nov 13, 2026), above 3, where the safe zone starts.
RVTY biggest customers
under 10%of sales from any one customerNo customer made 10% of Revvity's sales in fiscal 2025.
RVTY in past recessions
pretickt analysis-21%its sales in the worst oneRevvity's sales fell in 1 of the last 2 US recessions, by as much as 21% in fiscal 2009.
RVTY price vs profit P/E ratio
68.3×a year's earningsRevvity's P/E ratio is 68.3 (Nov 13, 2026), above its 3-year median of 46.5.
RVTY price vs competitors
pretickt analysis68.3×a year's earnings, against its competitorsInvestors pay 68.3 times Revvity's earnings (Nov 13, 2026), more than for Illumina (35.6), Labcorp (30.4) and Quest Diagnostics (25.9), less than for Charles River Laboratories (371.4).
RVTY analysts' target price target
-16%to their average targetAnalysts' average price target for Revvity is $129, 16% below the Nov 13, 2026 close of $154.39.
RVTY growth priced in fair value
pretickt analysis+12%a year, for ten years, to be worth the priceAt $154.39 a share, Revvity's free cash flow must grow about 12% a year for ten years to be worth the price (Nov 13, 2026).
What is Revvity's P/E ratio?
Revvity's P/E ratio is 68.3 (Nov 13, 2026), above its 3-year median of 46.5. Investors pay 68.3 times Revvity's earnings (Nov 13, 2026), more than for Illumina (35.6), Labcorp (30.4) and Quest Diagnostics (25.9), less than for Charles River Laboratories (371.4).
Who are Revvity's biggest competitors?
pretickt compares Revvity with Charles River Laboratories, Quest Diagnostics, Labcorp and Illumina. Revvity's sales grew 5% in the 12 months to Oct 4, 2026, faster than Charles River Laboratories (-1%), slower than Quest Diagnostics (+9%), Labcorp (+6%) and Illumina (+6%).
Is Revvity profitable?
Revvity's operating margin was 13% in the 12 months to Oct 4, 2026, against 24% in fiscal 2022.
Are insiders selling Revvity stock?
Revvity's executives and directors sold a net $5.97M of shares in the 12 months to Nov 13, 2026; none bought.
How does Revvity make money?
Life Sciences brought Revvity 50% of its sales in fiscal 2025; Diagnostics 50%.
How many employees does Revvity have?
Revvity had 11,000 employees at the end of fiscal 2025, about as many as a year before.
Who are Revvity's biggest customers?
No customer made 10% of Revvity's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.